Skip to main navigation
Skip to search
Skip to main content
Oregon Health & Science University Home
Help & FAQ
Home
Profiles
Research units
Core Facilities
Publications
Search by expertise, name or affiliation
Clinical aspects of imatinib therapy
B. J. Druker
Knight Cancer Institute
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical aspects of imatinib therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Imatinib Mesylate
76%
Clinical Trials
29%
PDGF receptor tyrosine kinase
18%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11%
Therapeutics
10%
Protein-Tyrosine Kinases
10%
Chronic Disease
8%
Neoplasms
3%
Chemical Compounds
Imatinib
100%
Tyrosine
20%